GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease
International Journal of Molecular Sciences · 21.03.2026 · 27 (6) · 2853
DOI: 10.3390/ijms27062853 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.03.2026. Verfasst von Ayush Gandhi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Circadian Rhythm, Metabolic Diseases, Sleep. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes and obesity, yet their actions extend beyond glycemic control and weight loss. This narrative review synthesizes current preclinical and clinical evidence examining the bidirectional relationship between glucagon-like peptide-1 (GLP-1) receptor agonists and circadian biology. A structured literature search was conducted in PubMed using combinations of the terms ‘GLP-1,’ ‘circadian,’ ‘chronobiology,’ ‘sleep,’ ‘obesity,’ and ‘type 2 diabetes’ through January 2026. Accumulating evidence indicates that GLP-1 physiology is closely coupled to circadian timing systems and sleep–wake regulation. In this narrative review, we synthesize emerging data that reframe GLP-1RAs as chronometabolic modulators, acting at the intersection of metabolism, circadian biology, and sleep. We review circadian control of GLP-1 secretion by intestinal L-cells, emphasizing the role of core clock genes and the vulnerability of incretin rhythms to circadian misalignment from shift work, nocturnal light exposure, and sleep loss. We then examine GLP-1 receptor signaling within central and peripheral clock networks, including feedback effects on hypothalamic and hepatic circadian regulation. Emerging data suggest that GLP-1 signaling is under circadian regulation and may, in turn, influence central and peripheral clock systems. Comparative discussion of semaglutide, liraglutide, and tirzepatide highlights agent-specific pharmacokinetics and emerging clinical data linking GLP-1RA therapy to sleep outcomes, particularly obstructive sleep apnea. Finally, we outline translational opportunities for chronotherapy and precision medicine, positioning GLP-1RAs as integrative tools for metabolic and sleep-related disease rather than purely weight-centric therapies. We propose that GLP-1 receptor agonists may function as chronometabolic modulators, with potential implications for personalized chronopharmacological strategies in metabolic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
ORCID-Profile: Ayush Gandhi, Kwame Koom-Dadzie
Zitieren
APA
Gandhi, A., Phyu, E. M., Koom-Dadzie, K., Dickson, K. B., & Halm, J. (2026). GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease. International Journal of Molecular Sciences, 27(6), 2853. https://doi.org/10.3390/ijms27062853
Vancouver
Gandhi A, Phyu EM, Koom-Dadzie K, Dickson KB, Halm J. GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease. International Journal of Molecular Sciences. 2026;27(6):2853. doi:10.3390/ijms27062853
BibTeX
@article{Gandhi2026,
author = {Gandhi, Ayush and Phyu, Ei Moe and Koom-Dadzie, Kwame and Dickson, Kodwo Bosomefi and Halm, Josiah},
title = {GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {6},
pages = {2853},
doi = {10.3390/ijms27062853}
}
EUVIMED